TG Therapeutics Inc (TGTX.OQ)
TGTX.OQ on NASDAQ Stock Exchange Capital Market
13.77USD
23 May 2018
13.77USD
23 May 2018
Change (% chg)
$-0.08 (-0.54%)
$-0.08 (-0.54%)
Prev Close
$13.85
$13.85
Open
$13.75
$13.75
Day's High
$14.20
$14.20
Day's Low
$13.70
$13.70
Volume
69,900
69,900
Avg. Vol
277,131
277,131
52-wk High
$17.30
$17.30
52-wk Low
$7.25
$7.25
About
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered... (more)
Overall
| Beta: | 1.34 |
| Market Cap(Mil.): | $846.68 |
| Shares Outstanding(Mil.): | 68.84 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| TGTX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 84.06 | 32.75 |
| EPS (TTM): | -1.95 | -- | -- |
| ROI: | -129.83 | 1.57 | 14.38 |
| ROE: | -133.51 | 2.43 | 16.07 |
BRIEF-TG Therapeutics Reports Qtrly Loss Per Share Of $0.59
* TG THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS
BRIEF-TG Therapeutics, Jiangsu Hengrui Announce Agreement For BTK Inhibitor Program For Treatment Of Hematologic Malignancies
* TG THERAPEUTICS AND JIANGSU HENGRUI MEDICINE ANNOUNCE GLOBAL LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NOVEL BTK INHIBITOR PROGRAM FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES
Competitors
| Price | Chg | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $123.45 | +0.54 |
| Novartis AG (NOVN.S) | CHF76.16 | -0.52 |
| Roche Holding Ltd. (ROG.S) | CHF219.25 | -4.65 |
| Roche Holding Ltd. (RO.S) | CHF223.40 | -5.40 |
| Merck & Co., Inc. (MRK.N) | $59.17 | +0.72 |
| Bayer AG (BAYGn.DE) | €102.74 | -2.30 |
| Bayer AG (BAYE.F) | -- | -- |
| Sanofi SA (SASY.PA) | €66.23 | -0.14 |
| Abbott Laboratories (ABT.N) | $61.84 | +0.45 |
| Alexion Pharmaceuticals, Inc. (ALXN.OQ) | $118.13 | -0.88 |
Estimates